[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"Fresenius Medical Care Holdings, Inc.\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":54},{"warningLetters":4,"total":53},[5,32],{"id":6,"raw":7,"subject":12,"body_html":14,"body_text":15,"firm_name":16,"letter_id":17,"created_at":18,"fei_number":19,"letter_url":20,"updated_at":21,"action_type":22,"case_status":23,"posted_date":24,"marcs_cms_no":25,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":27,"body_fetched_at":28,"delivery_method":29,"recipient_title":19,"reference_number":30,"action_taken_date":31,"medical_device_id":19,"response_letter_date":19},21643,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2026-09-01T04:00:00Z\">09\u002F01\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-08-25T04:00:00Z\">08\u002F25\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ffresenius-medical-care-ag-co-kgaa-730319-08252026\">Fresenius Medical Care AG &amp; Co. KGaA\u003C\u002Fa>","Center for Drug Evaluation and Research (CDER)","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated","","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email Return Receipt Requested\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-26-119\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Ms. Helen Giza\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Fresenius Medical Care AG &amp; Co. KGaA\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Else-Kröner-Straße 1\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>61352\u003C\u002Fspan> \u003Cspan>Bad Homburg v.d. Höhe\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Germany\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(4)\"> (b)(4)\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-26-119\u003C\u002Fp>\u003Cp>August 25, 2026\u003C\u002Fp>\u003Cp>Dear Ms. Giza:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Fresenius USA Manufacturing, Inc. dba Fresenius Medical Care North America Ogden Plant, FEI 1713747, at 475 W. 13th St., Ogden, Utah, from March 2 to 6, 2026.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>We reviewed your March 27, 2026, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\u003Cp>During our inspection, our investigator observed specific violations including, but not limited to, the following.\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You failed to adequately investigate customer complaints for the large volume parenteral (LVP) bag drug products you manufacture. Your investigations were not thorough and did not appropriately evaluate the risk to product quality. You also failed to identify and implement adequate and timely corrective actions and preventive actions (CAPAs).\u003C\u002Fp>\u003Cp>Specifically, in August 2025 you initiated an investigation due to a complaint trend for leaking bags of Delflex Peritoneal Dialysis Solution. This investigation noted that you eventually received 35 complaints covering approximately 156 bags from multiple batches. Your investigation attributed the bag leaks “to holes caused by printing.”\u003C\u002Fp>\u003Cp>Despite your Risk Management Matrix indicating peritonitis as a potential harm and recommending the highest severity level, you instead assigned the lowest severity level with the potential harm being “damage of property.” Although you ultimately conducted a recall in April 2026 after our inspection, you chose not to conduct a recall following the results of your August 2025 investigation.\u003C\u002Fp>\u003Cp>Your justifications for these decisions included: the lack of attributable peritonitis cases, product labeling instructed users to inspect bags for leaks, the leaks should be readily detected before treatment, and leaking fluid should collect in the overwrap.\u003C\u002Fp>\u003Cp>Notably, following our inspection, you state that you reexamined part of one batch and “found presence of perforations in the primary container without substantial fluid present in the overwrap,” demonstrating your error in assuming that users can consistently detect leaks. Moreover, users should not be relied upon to detect leaking bags. In addition, once you knew of the trend of leaking bags in marketed product, there should have been a commensurate increase in urgency to contain the issue.\u003C\u002Fp>\u003Cp>Your decision not to recall these batches at that time exposed peritoneal dialysis (PD) patients to potentially non-sterile drug products. The use of non-sterile PD solution elevates the risk of developing peritonitis, the clinical consequences of which may include serious and potentially life-threatening complications. In addition, a significant component in this drug, dextrose, could serve as a nutritional source for contaminating microorganisms and promote their growth.\u003C\u002Fp>\u003Cp>In your response, you acknowledge that the risk assessment should have been based on peritonitis risk, and you should not have assumed that users would detect any leaking unit. Your firm reassessed the risk for this incident and decided to recall the impacted lots. You also revised your procedure to assure that known and potential harms are evaluated during risk assessments.\u003C\u002Fp>\u003Cp>Your response is inadequate. It does not include a sufficient CAPA, including improving detection of leaking units during manufacturing to prevent their release and distribution. This is especially concerning considering the numerous complaints, Field Alert Reports, and recalled batches in the last three years for leaking LVP bags manufactured at your facility. Notably, two Field Alert Reports you previously submitted involved leaking LVP bags with microbial contamination.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive, independent assessment of the root causes of leaking bags including, but not limited to:\u003Cbr>o A failure mode analysis for the potential causes of leaking bags that addresses the deficiencies in the printing technology used by your firm, as well as any other potential causes associated with handling of bags by equipment and personnel\u003Cbr>o An independent review of your printing controls and their capabilities, including potential for contributing to leaking bags\u003Cbr>o An analysis of alternative printing technologies that can minimize or eliminate the printing step as a cause of leaking bags\u003Cbr>o CAPA to address the identified root causes of leaking bags, such as the replacement of the current printing technology\u003C\u002Fli>\u003Cli>A comprehensive assessment and remediation plan to ensure your quality unit (QU) is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003Cbr>o A determination of whether procedures used by your firm are robust and appropriate\u003Cbr>o Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\u003Cbr>o A complete and final review of each batch and its related information before the QU disposition decision\u003Cbr>o Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products\u003C\u002Fli>\u003Cli>A comprehensive assessment of your overall system for investigating deviations, discrepancies, complaints, out-of-specification results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, quality unit oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\u003C\u002Fli>\u003Cli>An independent review of in-process criteria for major and critical defects, including but not limited to leakers. Perform a retrospective evaluation, including:\u003Cbr>o A list of the number and types of all defects\u003Cbr>o Detailed long-term summaries (i.e., at least 5 years) of batch performance that address the period of recurring leaking incidents\u003Cbr>o All instances of batches with atypically high defects rates, with potential root cause of these deviations\u003C\u002Fli>\u003Cli>Provide a comprehensive process capability assessment of your manufacturing process, with special emphasis on the capability of critical operational steps including but not limited to the detection of leaking bags, and any related CAPA to be initiated in response to the capability assessment. Also, include an assessment of operator handling practices and machine stresses that could lead to loss of bag integrity.\u003C\u002Fli>\u003Cli>Provide a remediated program that provides for ongoing statistical assessment of processing line performance to vigilantly monitor state of control. Specifically, include your program for statistical process control of each batch of drug products manufactured by your firm to monitor intra-batch and inter-batch variation and promptly detect a drift in process control.\u003C\u002Fli>\u003Cli>Provide the protocol for and subsequent report from an independent review of the qualification report(s), validation report(s), and maintenance program for the equipment that forms, fills, and seals your drug product bags. Also include an independent review of the methods used to detect leaking bags throughout processing, the frequency of monitoring, and the validation report for each method.\u003C\u002Fli>\u003Cli>A detailed summary of your validation program for ensuring a state of control throughout the product lifecycle, along with associated procedures. Describe your program for process performance qualification, and ongoing vigilant monitoring of both intra-batch and inter-batch variation to ensure a continuing state of control. Also, describe your equipment and facility qualification program.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>2. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your visual inspection program was inadequate to ensure that sterile injectable drug products were essentially free of visible particulates. Specifically, you failed to appropriately qualify personnel who performed visual inspections of injectable products. Your visual inspection qualification kit did not include adequately representative visible particulates (e.g., size), and your qualification records lacked sufficient detail to determine the qualifications of staff who perform visual inspection of \u003Cstrong>(b)(4)\u003C\u002Fstrong> bags.\u003C\u002Fp>\u003Cp>Your response states that your visual inspection qualification kit contained representative particulates. You add that you are developing a new kit that will continue to contain such particles, and that you will periodically review production and post market data to verify the kit remains representative.\u003C\u002Fp>\u003Cp>Your response is inadequate. It does not address the failure of your visual inspection qualification program to demonstrate that visual inspection personnel can detect visible particles at a level that meets the appropriate standard. The example particles in your kit may not be representative of smaller particles in your drug products.\u003C\u002Fp>\u003Cp>Visual detection of particulates is a probabilistic process that depends on, among other things, ensuring that visible particulates can be reproducibly detected by trained personnel with appropriate visual acuity. Your qualification kit should contain particles of a size and composition that adequately challenge inspectors across the range of particulate sizes that may be present in your drug product and should be qualified to demonstrate that inspectors can reliably detect visible particulates relevant to your specific product and container\u002Fclosure system. These qualification kits should typically contain particles in the range of 100-150 microns to adequately challenge inspector detection capabilities.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A remediation plan that better assures ongoing management oversight throughout the manufacturing lifecycle of all drug products. Provide a more data-driven and scientifically sound program that identifies sources of process variability, and assures that manufacturing operations meet appropriate parameters and quality standards. This includes, but is not limited to, evaluating suitability of equipment for its intended use, ensuring quality of input materials, determining the capability and reliability of each manufacturing process step and its controls, and vigilant ongoing monitoring of process performance and product quality.\u003C\u002Fli>\u003Cli>A comprehensive, independent assessment and remediation plan for your visual inspection program to ensure compliance with CGMP. The remediation plan should include but not be limited to:\u003Cbr>o Improved visual inspection methods, as appropriate\u003Cbr>o Improved qualification protocols and associated records for all staff performing visual inspection\u003Cbr>o Incorporation of U.S. Pharmacopeia (USP) &lt;790&gt; Visible Particulates in Injections standards into your procedures\u003Cbr>o Use of an appropriate range of visible particulate types and sizes, including particles of also approximately 100-150 microns, as part of staff qualification studies\u003Cbr>o All other provisions necessary to ensure appropriate qualification of visual particulate inspectors\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>Drug Recall\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>On April 6, 2026, you issued voluntary recalls of DELFLEX Dextrose Peritoneal Dialysis Solution due to Lack of Assurance of Sterility. The company announcements were posted to the FDA website:\u003Cbr>https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fires\u002Findex.cfm?Product=219904\u003Cbr>https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fires\u002Findex.cfm?Product=219905\u003C\u002Fp>\u003Cp>\u003Cstrong>CGMP Consultant\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\u003Cp>If you are considering an action that is likely to lead to a disruption in the supply of drugs produced at your facility, FDA requests that you contact CDER’s Drug Shortages Staff immediately, at drugshortages@fda.hhs.gov, so that FDA can work with you on the most effective way to bring your operations into compliance with the law. Contacting the Drug\u003C\u002Fp>\u003Cp>Shortages Staff also allows you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture under 21 U.S.C. 356C(b). This also allows FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who depend on your products.\u003C\u002Fp>\u003Cp>Correct any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\u003Cp>Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 1713747 and ATTN: Russell Riley.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\u003Cp>CC: Mr. Brett A. Barton\u003Cbr>General Manager\u003Cbr>Vice President of Manufacturing Operations Ogden Plant\u003Cbr>Fresenius USA Manufacturing, Inc. dba Fresenius Medical Care North America Ogden Plant\u003Cbr>Email: \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>________________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Under program enhancements for the Generic Drug User Fee Amendments (GDUFA) reauthorization for fiscal years (FYs) 2023-2027, also known as the GDUFA III Commitment Letter, your facility may be eligible for a Post-Warning Letter Meeting to obtain preliminary feedback from FDA on the adequacy and completeness of your corrective action plans.\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email Return Receipt Requested\n\nReference #:\n\n320-26-119\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMs. Helen Giza\n\nRecipient Title\n\nChief Executive Officer\n\nFresenius Medical Care AG & Co. KGaA\n\nElse-Kröner-Straße 1\n\n61352 Bad Homburg v.d. Höhe\n\nGermany\n\n(b)(4)\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-26-119\nAugust 25, 2026\nDear Ms. Giza:\nThe United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Fresenius USA Manufacturing, Inc. dba Fresenius Medical Care North America Ogden Plant, FEI 1713747, at 475 W. 13th St., Ogden, Utah, from March 2 to 6, 2026.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\nWe reviewed your March 27, 2026, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\nDuring our inspection, our investigator observed specific violations including, but not limited to, the following.\n1. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\nYou failed to adequately investigate customer complaints for the large volume parenteral (LVP) bag drug products you manufacture. Your investigations were not thorough and did not appropriately evaluate the risk to product quality. You also failed to identify and implement adequate and timely corrective actions and preventive actions (CAPAs).\nSpecifically, in August 2025 you initiated an investigation due to a complaint trend for leaking bags of Delflex Peritoneal Dialysis Solution. This investigation noted that you eventually received 35 complaints covering approximately 156 bags from multiple batches. Your investigation attributed the bag leaks “to holes caused by printing.”\nDespite your Risk Management Matrix indicating peritonitis as a potential harm and recommending the highest severity level, you instead assigned the lowest severity level with the potential harm being “damage of property.” Although you ultimately conducted a recall in April 2026 after our inspection, you chose not to conduct a recall following the results of your August 2025 investigation.\nYour justifications for these decisions included: the lack of attributable peritonitis cases, product labeling instructed users to inspect bags for leaks, the leaks should be readily detected before treatment, and leaking fluid should collect in the overwrap.\nNotably, following our inspection, you state that you reexamined part of one batch and “found presence of perforations in the primary container without substantial fluid present in the overwrap,” demonstrating your error in assuming that users can consistently detect leaks. Moreover, users should not be relied upon to detect leaking bags. In addition, once you knew of the trend of leaking bags in marketed product, there should have been a commensurate increase in urgency to contain the issue.\nYour decision not to recall these batches at that time exposed peritoneal dialysis (PD) patients to potentially non-sterile drug products. The use of non-sterile PD solution elevates the risk of developing peritonitis, the clinical consequences of which may include serious and potentially life-threatening complications. In addition, a significant component in this drug, dextrose, could serve as a nutritional source for contaminating microorganisms and promote their growth.\nIn your response, you acknowledge that the risk assessment should have been based on peritonitis risk, and you should not have assumed that users would detect any leaking unit. Your firm reassessed the risk for this incident and decided to recall the impacted lots. You also revised your procedure to assure that known and potential harms are evaluated during risk assessments.\nYour response is inadequate. It does not include a sufficient CAPA, including improving detection of leaking units during manufacturing to prevent their release and distribution. This is especially concerning considering the numerous complaints, Field Alert Reports, and recalled batches in the last three years for leaking LVP bags manufactured at your facility. Notably, two Field Alert Reports you previously submitted involved leaking LVP bags with microbial contamination.\nIn response to this letter, provide:\nA comprehensive, independent assessment of the root causes of leaking bags including, but not limited to:\no A failure mode analysis for the potential causes of leaking bags that addresses the deficiencies in the printing technology used by your firm, as well as any other potential causes associated with handling of bags by equipment and personnel\no An independent review of your printing controls and their capabilities, including potential for contributing to leaking bags\no An analysis of alternative printing technologies that can minimize or eliminate the printing step as a cause of leaking bags\no CAPA to address the identified root causes of leaking bags, such as the replacement of the current printing technology\nA comprehensive assessment and remediation plan to ensure your quality unit (QU) is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\no A determination of whether procedures used by your firm are robust and appropriate\no Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\no A complete and final review of each batch and its related information before the QU disposition decision\no Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products\nA comprehensive assessment of your overall system for investigating deviations, discrepancies, complaints, out-of-specification results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, quality unit oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\nAn independent review of in-process criteria for major and critical defects, including but not limited to leakers. Perform a retrospective evaluation, including:\no A list of the number and types of all defects\no Detailed long-term summaries (i.e., at least 5 years) of batch performance that address the period of recurring leaking incidents\no All instances of batches with atypically high defects rates, with potential root cause of these deviations\nProvide a comprehensive process capability assessment of your manufacturing process, with special emphasis on the capability of critical operational steps including but not limited to the detection of leaking bags, and any related CAPA to be initiated in response to the capability assessment. Also, include an assessment of operator handling practices and machine stresses that could lead to loss of bag integrity.\nProvide a remediated program that provides for ongoing statistical assessment of processing line performance to vigilantly monitor state of control. Specifically, include your program for statistical process control of each batch of drug products manufactured by your firm to monitor intra-batch and inter-batch variation and promptly detect a drift in process control.\nProvide the protocol for and subsequent report from an independent review of the qualification report(s), validation report(s), and maintenance program for the equipment that forms, fills, and seals your drug product bags. Also include an independent review of the methods used to detect leaking bags throughout processing, the frequency of monitoring, and the validation report for each method.\nA detailed summary of your validation program for ensuring a state of control throughout the product lifecycle, along with associated procedures. Describe your program for process performance qualification, and ongoing vigilant monitoring of both intra-batch and inter-batch variation to ensure a continuing state of control. Also, describe your equipment and facility qualification program.\n2. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\nYour visual inspection program was inadequate to ensure that sterile injectable drug products were essentially free of visible particulates. Specifically, you failed to appropriately qualify personnel who performed visual inspections of injectable products. Your visual inspection qualification kit did not include adequately representative visible particulates (e.g., size), and your qualification records lacked sufficient detail to determine the qualifications of staff who perform visual inspection of (b)(4) bags.\nYour response states that your visual inspection qualification kit contained representative particulates. You add that you are developing a new kit that will continue to contain such particles, and that you will periodically review production and post market data to verify the kit remains representative.\nYour response is inadequate. It does not address the failure of your visual inspection qualification program to demonstrate that visual inspection personnel can detect visible particles at a level that meets the appropriate standard. The example particles in your kit may not be representative of smaller particles in your drug products.\nVisual detection of particulates is a probabilistic process that depends on, among other things, ensuring that visible particulates can be reproducibly detected by trained personnel with appropriate visual acuity. Your qualification kit should contain particles of a size and composition that adequately challenge inspectors across the range of particulate sizes that may be present in your drug product and should be qualified to demonstrate that inspectors can reliably detect visible particulates relevant to your specific product and container\u002Fclosure system. These qualification kits should typically contain particles in the range of 100-150 microns to adequately challenge inspector detection capabilities.\nIn response to this letter, provide:\nA remediation plan that better assures ongoing management oversight throughout the manufacturing lifecycle of all drug products. Provide a more data-driven and scientifically sound program that identifies sources of process variability, and assures that manufacturing operations meet appropriate parameters and quality standards. This includes, but is not limited to, evaluating suitability of equipment for its intended use, ensuring quality of input materials, determining the capability and reliability of each manufacturing process step and its controls, and vigilant ongoing monitoring of process performance and product quality.\nA comprehensive, independent assessment and remediation plan for your visual inspection program to ensure compliance with CGMP. The remediation plan should include but not be limited to:\no Improved visual inspection methods, as appropriate\no Improved qualification protocols and associated records for all staff performing visual inspection\no Incorporation of U.S. Pharmacopeia (USP) \u003C790> Visible Particulates in Injections standards into your procedures\no Use of an appropriate range of visible particulate types and sizes, including particles of also approximately 100-150 microns, as part of staff qualification studies\no All other provisions necessary to ensure appropriate qualification of visual particulate inspectors\nDrug Recall\nOn April 6, 2026, you issued voluntary recalls of DELFLEX Dextrose Peritoneal Dialysis Solution due to Lack of Assurance of Sterility. The company announcements were posted to the FDA website:\nhttps:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fires\u002Findex.cfm?Product=219904\nhttps:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fires\u002Findex.cfm?Product=219905\nCGMP Consultant\nBased upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit1 of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA.\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\nIf you are considering an action that is likely to lead to a disruption in the supply of drugs produced at your facility, FDA requests that you contact CDER’s Drug Shortages Staff immediately, at drugshortages@fda.hhs.gov, so that FDA can work with you on the most effective way to bring your operations into compliance with the law. Contacting the Drug\nShortages Staff also allows you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture under 21 U.S.C. 356C(b). This also allows FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who depend on your products.\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\nFailure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days1. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 1713747 and ATTN: Russell Riley.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research\nCC: Mr. Brett A. Barton\nGeneral Manager\nVice President of Manufacturing Operations Ogden Plant\nFresenius USA Manufacturing, Inc. dba Fresenius Medical Care North America Ogden Plant\nEmail: (b)(4)\n________________________\n1 Under program enhancements for the Generic Drug User Fee Amendments (GDUFA) reauthorization for fiscal years (FYs) 2023-2027, also known as the GDUFA III Commitment Letter, your facility may be eligible for a Post-Warning Letter Meeting to obtain preliminary feedback from FDA on the adequacy and completeness of your corrective action plans.","Fresenius Medical Care AG & Co. KGaA","fresenius-medical-care-ag-co-kgaa-730319-08252026","2026-09-07T05:14:13.57002+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ffresenius-medical-care-ag-co-kgaa-730319-08252026","2026-10-26T08:08:43.502309+00:00","Warning Letter","Issued","2026-09-01","730319","Drugs","Ms. Helen Giza","2026-09-07T05:14:22.608+00:00","Via Email Return Receipt Requested","320-26-119","2026-08-25",{"id":33,"raw":34,"subject":39,"body_html":40,"body_text":41,"firm_name":16,"letter_id":42,"created_at":43,"fei_number":19,"letter_url":44,"updated_at":45,"action_type":22,"case_status":23,"posted_date":46,"marcs_cms_no":47,"product_type":48,"closeout_date":19,"issuing_office":38,"recipient_name":49,"body_fetched_at":50,"delivery_method":51,"recipient_title":19,"reference_number":19,"action_taken_date":52,"medical_device_id":19,"response_letter_date":19},1690,[35,36,37,38,39,13,13,13],"\u003Ctime datetime=\"2023-12-19T14:20:00Z\">12\u002F19\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-12-04T05:00:00Z\">12\u002F04\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ffresenius-medical-care-ag-co-kgaa-666791-12042023\">Fresenius Medical Care AG &amp; Co. KGaA\u003C\u002Fa>","Center for Devices and Radiological Health","CGMP\u002FQSR\u002FMedical Devices\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>United Parcel Service\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Helen Giza\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Fresenius Medical Care AG &amp; Co. KGaA\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Else-Kröner-Straße 1\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Bad Homburg v.d.\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>61352\u003C\u002Fspan> \u003Cspan>Höhe\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Germany\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n  \u003Cdiv>\n    \u003Cdiv>Secondary Issuing Offices\u003C\u002Fdiv>\n          \u003Cdiv>\n              \u003Cdiv>    \u003Cbr>\n    \n     \n        \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n    \n    \n    \n    \n\u003C\u002Fdiv>\n              \u003C\u002Fdiv>\n      \u003C\u002Fdiv>\n\n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003Cbr>\nCMS # 666791\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>December 4, 2023\u003Cbr>\n\u003Cbr>\nDear Ms. Giza:\u003C\u002Fp>\n\n\u003Cp>The United States Food and Drug Administration (FDA) conducted an inspection of your firm’s medical device operations, Fresenius Medical Care Holdings, Inc. (Fresenius), d.b.a. Fresenius Care North America, located at 920 Winter Street, Building 920, Waltham, MA 02451-1521, from June 26, 2023, through August 2, 2023. During the inspection, FDA investigators determined that your firm is a medical device specification developer responsible for complaint handling, recall management, and quality system oversite of your North American manufacturing of dialysis systems and accessories, such as the 2008 Series Hemodialysis Machine. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\n\n\u003Cp>This inspection revealed that the above devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820, and Title 21 CFR Part 806, Medical Devices, Reports of Corrections and Removals.\u003C\u002Fp>\n\n\u003Cp>We received your responses dated August 24, 2023, and September 22, 2023, from Kathleen Storro, Vice President, Quality Management System, North America, which responded to the Form FDA 483, List of Inspectional Observations issued to your firm on August 2, 2023. We address your responses below.\u003C\u002Fp>\n\n\u003Cp>Violations include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>1. Failure to establish and maintain procedures for implementing corrective and preventive actions, as required by 820.100(a). Specifically, your Corrective Action and Preventive Action, Procedure No. S100016-03, Rev E. Dated January 30, 2023, is inadequate in that:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>You did not take a corrective and preventative action until almost 2-years after you learned of a potential issue impacting your Hemodialysis Machines that contain peroxide crosslinked silicone tubing. You were notified on December 3, 2020, of PCB emissions that were detected from the peroxide crosslinked silicone tubing component, and you did not open CAPA 1100660 until June 15, 2022. The devices were not recalled until November 25, 2022.\u003C\u002Fli>\n\t\u003Cli>You failed to adequately investigate the potential health impact of PCB related compounds leaching from the components of your 2008 K, 2008 K2 and 2008 T Hemodialysis Machines that use peroxide crosslinked silicone tubing. The risk calculation you performed to determine the risk level of PCB related compounds leaching was inadequate to determine the overall risk of the device. You did not include the minimum body weight of 20 kg, as listed in the instructions for use (IFU) when calculating the Health Hazard Assessment (HHA-FA-2022-19-W) for the 2008 series of Hemodialysis Machines with peroxide crosslinked silicone tubing.\u003C\u002Fli>\n\t\u003Cli>You failed to verify the corrective actions were effective for CAPA 932073, as required by your CAPA procedure. CAPA 932073 resulted in a recall of the 2008T and 2008T Bluestar Hemodialysis Machine with CDX-Indicated for acute and chronic dialysis therapy due the false alarm \"Remove USB 2 Device\" (RES 91154).\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>We reviewed your firm’s responses and have concluded that the adequacy of your response cannot be determined at this time because you have not completed your proposed corrective and preventive actions. Please provide an update on the status of your corrective actions.\u003C\u002Fp>\n\n\u003Cp>2. Failure to document all activities and their results required under this section (Corrective and preventive action) as required by 21 CFR 820.100(b). Specifically:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>CAPA 1100660 dated June 15, 2022, opened for the PCB related compounds issue failed to adequately document all the activities you performed after you became aware of PCB related compounds finding. The CAPA states that there are no actions required however you had action plans for PCB related compounds which you implemented via design change, product hold and a rework which were covered by NCs 1145819 and 1150080 and Quality Event 1057552. Your CAPA also failed to document your first awareness of PCB related compounds finding in peroxide crosslinked silicone which you received from your supplier. As well as corrections to distributed devices, which you initiated on November 25, 2022, to update\u002Fcorrect the silicone tubing.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>We reviewed your firm’s responses and have concluded that the adequacy of your response cannot be determined at this time because you have not completed your proposed corrective and preventive actions. Please provide an update on the status of your corrective actions.\u003C\u002Fp>\n\n\u003Cp>3. Failure to establish and maintain procedures for validating the device design, as required by 21 CFR 820.30(g). Specifically, Design Validation Procedure, S100021-13, was not followed when conducting retrospective design validation of your 2008T, 2008 K and 2008 K2 Hemodialysis Machines to determine if the devices can be used safely and effectively by the intended users. \u003Cstrong>(b)(4)\u003C\u002Fstrong> rounds of real-world studies were conducted to detect PCB related compounds, and if detected, determine which day of use the PCBs were detected. For example:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Failure to establish the protocols for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> rounds of studies and for round&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> failed to adequately establish the protocol.\u003C\u002Fli>\n\t\u003Cli>The test method was not specific regarding background blank dialysate usage to repeating the test.\u003C\u002Fli>\n\t\u003Cli>The round \u003Cstrong>(b)(4)\u003C\u002Fstrong> study, initial results found PCB related compounds present after 60 days of usage; however, the device was later identified as never have been used.\u003C\u002Fli>\n\t\u003Cli>Samples were collected for \u003Cstrong>(b)(4)\u003C\u002Fstrong> for the study; however, the protocol identifies samples were to be collected for \u003Cstrong>(b)(4)\u003C\u002Fstrong> only. You failed to update the protocol when they made changes.\u003C\u002Fli>\n\t\u003Cli>Failure to approve the protocol before performing the formal validation.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>We reviewed your firm’s responses and have concluded that the adequacy of your response cannot be determined at this time because you have not completed your proposed corrective and preventive actions. Please provide an update on the status of your corrective actions.\u003C\u002Fp>\n\n\u003Cp>Exposure to PCBs can have long-term health consequences linked to hepatic effects (including serum hepatic enzyme elevation), dermal changes (acne, rashes), certain cancer (e.g., liver, gallbladder, biliary tract, gastrointestinal tract, brain, malignant melanoma, non-Hodgkin’s lymphoma), neurodevelopmental and behavioral toxicity via lactational exposure, endocrine dysfunction (thyroid), neurobehavioral alterations, immune system alterations, anemia, and male reproductive effects. Additionally, patients with end stage renal disease on dialysis are vulnerable and adverse events may get magnified or present differently in this population due to their altered physiology.\u003C\u002Fp>\n\n\u003Cp>Our inspection also revealed that your firm’s hemodialysis machines are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 806 – Medical Devices; Reports of Corrections and Removals. Significant violations include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>4. A correction or removal, conducted to reduce a risk to health posed by a device, was not reported in writing to FDA within 10-working days of initiating such correction or removal, as required by 21 CFR 806.10(b). Specifically, to reduce a risk to health posed by the device, you initiated a field action starting on November 25, 2022, for your 2008 Hemodialysis Machines by going to customers’ sites to change the silicone tubing associated with PCBA related compounds leaching. As of the time of the recent inspection, you have updated \u003Cstrong>(b)(4)\u003C\u002Fstrong> Hemodialysis Machines with a new silicone tubing “platinum cross linked silicon” without a formal notice to FDA. You field corrected the devices after FDA published a safety communication on potential risk of exposure to toxic compounds when using certain hemodialysis machines manufactured by Fresenius Medical Care.\u003C\u002Fp>\n\n\u003Cp>Our office confirms receipt of your letter, dated September 6, 2023, Report of Corrections and Removal (RES 92788). We reviewed your firm’s responses and have concluded that the adequacy of your response cannot be determined at this time. Your responses state that CAPA 1472083 has been opened and root cause investigation, appropriate process improvements to S100036-01, Coordinating Field Corrections, Removals, or Recalls, will be implemented, as necessary. Please provide an update on the status of this CAPA.\u003C\u002Fp>\n\n\u003Cp>Your firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\n\n\u003Cp>Other federal agencies may take your compliance with the Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\u003C\u002Fp>\n\n\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed.\u003C\u002Fp>\n\n\u003Cp>Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\n\n\u003Cp>Your firm’s response should be sent to: Gina Brackett, Director of Compliance Branch, at oradevices1firmresponse@fda.hhs.gov. Refer to CMS # 666791 when replying. If you have any questions about the contents of this letter, please contact Compliance Officer, Richard\u003Cbr>\nCherry at 215-717-3075 or at richard.cherry@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Joseph Matrisciano, Jr.\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Medical Device and Radiological\u003Cbr>\nHealth Division 1\u003C\u002Fp>\n\n\u003Cp>\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Courtney H. Lias, Ph.D.\u003Cbr>\nDirector\u003Cbr>\nOHT3: Office of GastroRenal, ObGyn, General\u003Cbr>\nHospital and Urology Devices Office of\u003Cbr>\nProduct Evaluation and Quality Center for\u003Cbr>\nDevices and Radiological Health\u003C\u002Fp>\n\n\u003Cp>cc: Linda J. Jalbert, Senior Vice President, Medical Safety and Postmarket Systems\u003Cbr>\nFresenius Medical Care Holdings, Inc.\u003Cbr>\n920 Winter Street, Bld. 920\u003Cbr>\nWaltham, MA 02451-1521\u003Cbr>\n(UPS overnight delivery)\u003C\u002Fp>\n\n\u003Cp>Kathleen Storro, Vice President Quality Management System, North America\u003Cbr>\nFresenius Medical Care Holdings, Inc.\u003Cbr>\n920 Winter Street, Bld. 920\u003Cbr>\nWaltham, MA 02451-1521\u003Cbr>\n(UPS overnight delivery)\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nUnited Parcel Service\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nHelen Giza\n\nRecipient Title\n\nCEO\n\nFresenius Medical Care AG & Co. KGaA\n\nElse-Kröner-Straße 1\n\nBad Homburg v.d.\n\n61352 Höhe\n\nGermany\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nSecondary Issuing Offices\n\nUnited States\n\nWARNING LETTER\n\nCMS # 666791\n\nDecember 4, 2023\n\nDear Ms. Giza:\n\nThe United States Food and Drug Administration (FDA) conducted an inspection of your firm’s medical device operations, Fresenius Medical Care Holdings, Inc. (Fresenius), d.b.a. Fresenius Care North America, located at 920 Winter Street, Building 920, Waltham, MA 02451-1521, from June 26, 2023, through August 2, 2023. During the inspection, FDA investigators determined that your firm is a medical device specification developer responsible for complaint handling, recall management, and quality system oversite of your North American manufacturing of dialysis systems and accessories, such as the 2008 Series Hemodialysis Machine. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\n\nThis inspection revealed that the above devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820, and Title 21 CFR Part 806, Medical Devices, Reports of Corrections and Removals.\n\nWe received your responses dated August 24, 2023, and September 22, 2023, from Kathleen Storro, Vice President, Quality Management System, North America, which responded to the Form FDA 483, List of Inspectional Observations issued to your firm on August 2, 2023. We address your responses below.\n\nViolations include, but are not limited to, the following:\n\n1. Failure to establish and maintain procedures for implementing corrective and preventive actions, as required by 820.100(a). Specifically, your Corrective Action and Preventive Action, Procedure No. S100016-03, Rev E. Dated January 30, 2023, is inadequate in that:\n\nYou did not take a corrective and preventative action until almost 2-years after you learned of a potential issue impacting your Hemodialysis Machines that contain peroxide crosslinked silicone tubing. You were notified on December 3, 2020, of PCB emissions that were detected from the peroxide crosslinked silicone tubing component, and you did not open CAPA 1100660 until June 15, 2022. The devices were not recalled until November 25, 2022.\n\nYou failed to adequately investigate the potential health impact of PCB related compounds leaching from the components of your 2008 K, 2008 K2 and 2008 T Hemodialysis Machines that use peroxide crosslinked silicone tubing. The risk calculation you performed to determine the risk level of PCB related compounds leaching was inadequate to determine the overall risk of the device. You did not include the minimum body weight of 20 kg, as listed in the instructions for use (IFU) when calculating the Health Hazard Assessment (HHA-FA-2022-19-W) for the 2008 series of Hemodialysis Machines with peroxide crosslinked silicone tubing.\n\nYou failed to verify the corrective actions were effective for CAPA 932073, as required by your CAPA procedure. CAPA 932073 resulted in a recall of the 2008T and 2008T Bluestar Hemodialysis Machine with CDX-Indicated for acute and chronic dialysis therapy due the false alarm \"Remove USB 2 Device\" (RES 91154).\n\nWe reviewed your firm’s responses and have concluded that the adequacy of your response cannot be determined at this time because you have not completed your proposed corrective and preventive actions. Please provide an update on the status of your corrective actions.\n\n2. Failure to document all activities and their results required under this section (Corrective and preventive action) as required by 21 CFR 820.100(b). Specifically:\n\nCAPA 1100660 dated June 15, 2022, opened for the PCB related compounds issue failed to adequately document all the activities you performed after you became aware of PCB related compounds finding. The CAPA states that there are no actions required however you had action plans for PCB related compounds which you implemented via design change, product hold and a rework which were covered by NCs 1145819 and 1150080 and Quality Event 1057552. Your CAPA also failed to document your first awareness of PCB related compounds finding in peroxide crosslinked silicone which you received from your supplier. As well as corrections to distributed devices, which you initiated on November 25, 2022, to update\u002Fcorrect the silicone tubing.\n\nWe reviewed your firm’s responses and have concluded that the adequacy of your response cannot be determined at this time because you have not completed your proposed corrective and preventive actions. Please provide an update on the status of your corrective actions.\n\n3. Failure to establish and maintain procedures for validating the device design, as required by 21 CFR 820.30(g). Specifically, Design Validation Procedure, S100021-13, was not followed when conducting retrospective design validation of your 2008T, 2008 K and 2008 K2 Hemodialysis Machines to determine if the devices can be used safely and effectively by the intended users. (b)(4) rounds of real-world studies were conducted to detect PCB related compounds, and if detected, determine which day of use the PCBs were detected. For example:\n\nFailure to establish the protocols for the (b)(4) rounds of studies and for round (b)(4) failed to adequately establish the protocol.\n\nThe test method was not specific regarding background blank dialysate usage to repeating the test.\n\nThe round (b)(4) study, initial results found PCB related compounds present after 60 days of usage; however, the device was later identified as never have been used.\n\nSamples were collected for (b)(4) for the study; however, the protocol identifies samples were to be collected for (b)(4) only. You failed to update the protocol when they made changes.\n\nFailure to approve the protocol before performing the formal validation.\n\nWe reviewed your firm’s responses and have concluded that the adequacy of your response cannot be determined at this time because you have not completed your proposed corrective and preventive actions. Please provide an update on the status of your corrective actions.\n\nExposure to PCBs can have long-term health consequences linked to hepatic effects (including serum hepatic enzyme elevation), dermal changes (acne, rashes), certain cancer (e.g., liver, gallbladder, biliary tract, gastrointestinal tract, brain, malignant melanoma, non-Hodgkin’s lymphoma), neurodevelopmental and behavioral toxicity via lactational exposure, endocrine dysfunction (thyroid), neurobehavioral alterations, immune system alterations, anemia, and male reproductive effects. Additionally, patients with end stage renal disease on dialysis are vulnerable and adverse events may get magnified or present differently in this population due to their altered physiology.\n\nOur inspection also revealed that your firm’s hemodialysis machines are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 806 – Medical Devices; Reports of Corrections and Removals. Significant violations include, but are not limited to, the following:\n\n4. A correction or removal, conducted to reduce a risk to health posed by a device, was not reported in writing to FDA within 10-working days of initiating such correction or removal, as required by 21 CFR 806.10(b). Specifically, to reduce a risk to health posed by the device, you initiated a field action starting on November 25, 2022, for your 2008 Hemodialysis Machines by going to customers’ sites to change the silicone tubing associated with PCBA related compounds leaching. As of the time of the recent inspection, you have updated (b)(4) Hemodialysis Machines with a new silicone tubing “platinum cross linked silicon” without a formal notice to FDA. You field corrected the devices after FDA published a safety communication on potential risk of exposure to toxic compounds when using certain hemodialysis machines manufactured by Fresenius Medical Care.\n\nOur office confirms receipt of your letter, dated September 6, 2023, Report of Corrections and Removal (RES 92788). We reviewed your firm’s responses and have concluded that the adequacy of your response cannot be determined at this time. Your responses state that CAPA 1472083 has been opened and root cause investigation, appropriate process improvements to S100036-01, Coordinating Field Corrections, Removals, or Recalls, will be implemented, as necessary. Please provide an update on the status of this CAPA.\n\nYour firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\n\nOther federal agencies may take your compliance with the Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\n\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed.\n\nYour firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration as part of your response.\n\nYour firm’s response should be sent to: Gina Brackett, Director of Compliance Branch, at oradevices1firmresponse@fda.hhs.gov. Refer to CMS # 666791 when replying. If you have any questions about the contents of this letter, please contact Compliance Officer, Richard\n\nCherry at 215-717-3075 or at richard.cherry@fda.hhs.gov.\n\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\n\nSincerely,\n\n\u002FS\u002F\n\nJoseph Matrisciano, Jr.\n\nProgram Division Director\n\nOffice of Medical Device and Radiological\n\nHealth Division 1\n\n\u002FS\u002F\n\nCourtney H. Lias, Ph.D.\n\nDirector\n\nOHT3: Office of GastroRenal, ObGyn, General\n\nHospital and Urology Devices Office of\n\nProduct Evaluation and Quality Center for\n\nDevices and Radiological Health\n\ncc: Linda J. Jalbert, Senior Vice President, Medical Safety and Postmarket Systems\n\nFresenius Medical Care Holdings, Inc.\n\n920 Winter Street, Bld. 920\n\nWaltham, MA 02451-1521\n\n(UPS overnight delivery)\n\nKathleen Storro, Vice President Quality Management System, North America\n\nFresenius Medical Care Holdings, Inc.\n\n920 Winter Street, Bld. 920\n\nWaltham, MA 02451-1521\n\n(UPS overnight delivery)","fresenius-medical-care-ag-co-kgaa-666791-12042023","2026-08-18T06:42:28.994808+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ffresenius-medical-care-ag-co-kgaa-666791-12042023","2026-10-26T08:08:43.457936+00:00","2023-12-19","666791","Medical Devices","Helen Giza","2026-08-20T00:26:00.628+00:00","United Parcel Service","2023-12-04",2,{"510k":55,"classification":56,"enforcement":57,"event":58,"event_backfill":59,"pma":60,"warning_letter":61},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-17T04:00:34.414+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]